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Abstract 
We have characterized the 5' end of the rat gene encoding isoform 3 of the plasma membrane Ca2+-ATPase using SI nuclease 
protection and DNA sequence analysis. The 5'-untranslated region consists of over 900 nucleotides and includes a 217-nucleotide 
sequence composed of alternating tracts of TCC and ACC trinucleotides. Analysis of genomic sequences 5' to the transcription i itiation 
site revealed potential binding sites for transcription factors that are active in muscle and brain. 
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Calmodulin-sensitive plasma membrane Ca 2 +-transport- 
ing ATPases are encoded by four distinct genes [1-6], 
each of which gives rise to multiple PMCA variants by 
alternative splicing of one or more exons [7-14]. PMCA1 
and PMCA4 are expressed in most rat tissues [3,6], whereas 
PMCA2 is expressed primarily in brain and heart [3], and 
PMCA3 is expressed primarily in brain and skeletal mus- 
cle [3,12]. To begin the analysis of its genetic regulation 
we recently characterized the structure of the PMCA3 gene 
[12], however, our attempts to identify the transcription 
initiation site were unsuccessful due to the presence of an 
extensive trinucleotide repeat sequence at the 5' end of the 
gene. 
Interestingly, trinucleotide repeat sequences located in 
both coding and untranslated regions have been shown to 
be involved in a number of human genetic diseases, such 
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as Fragile X Syndrome [ 15], Myotonic Dystrophy [ 16], and 
Huntington's Disease [17]. The human PMCA3 gene has 
been mapped to the Xq28 region of the X chromosome 
[18]. The disease genes for a number of X-linked neurolog- 
ical and skeletal muscle disorders have been mapped to 
this region [19], and if PMCA3 is involved in any of these 
diseases it is conceivable that the trinucleotide repeat 
sequence could be involved. Thus, one objective of the 
current study was to characterize the repeat sequence and 
determine whether it was included within the transcribed 
region of the gene and within the mature mRNA. 
Because the plasma membrane calcium pumps play a 
critical role in cellular calcium homeostasis the regulation 
of their expression is of considerable interest. However, 
identification and analysis of the transcriptional control 
regions of the PMCA genes have been hampered by the 
presence of large introns in the untranslated regions [12,13], 
by GC-rich sequences in the case of the PMCAI gene [13], 
and by the trinucleotide repeat sequence in the case of 
PMCA3 [12]. Thus, a second objective of this study was to 
identify the promoter region of the PMCA3 gene. 
Rat brain cDNA clone RB 7-2, the longest PMCA3 
cDNA identified in one of our previous studies [3], con- 
tained a lengthy Y-untranslated sequence that extended to 
nucleotide -695  relative to the translation initiation site. 
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When we characterized the organization of the PMCA3 
gene [12] we determined that the 5'-untranslated sequence 
was distributed over at least 3 exons separated by introns 
of 3.5 and 16.5 kb and that the 5' end of the PMCA3 
cDNA began at the end of a complex trinucleotide repeat 
sequence of over 200 nucleotides. Based on data from 
these earlier studies it was clear that at least a portion of 
the trinucleotide sequence was included in the transcribed 
region of the gene, and it seemed likely that transcription 
would begin upstream of the repeat element rather than 
within it. 
To determine the sequence of both the trinucleotide 
repeat region, as well as the upstream flanking region that 
seemed likely to contain the promoter, we analyzed a 
cosmid clone containing genomic sequences upstream of 
the 5'-most exon identified previously [12]. A PstI frag- 
ment extending 2.8 kb upstream from the known se- 
quences of exon 1 was subcloned into a plasmid vector 
and most of the sequence was determined in both strands 
by the dideoxy chain-termination method [20] using T7 
DNA polymerase. However, because the trinucleotide re- 
peat sequence was refractory to analysis using the chain 
termination procedure the chemical cleavage procedure 
[21] was also used. 
As illustrated in Fig. 1, sequence analysis by chemical 
cleavage revealed a striking pattern of alternating 
trinucleotide repeat sequences extending from position 
-905  to -687  relative to the translation initiation site 
(also see Fig. 4). It begins with a 57-nucleotide sequence 
consisting of TCC trinucleotides, which is followed by a 
30-nucleotide sequence consisting of ACC trinucleotides. 
The ACC repeat is followed by a 28-nucleotide sequence 
consisting primarily of TCC trinucleotides with a mirror 
repeat in the middle of the pattern having the sequence 
CCCTCTTCTCCC. Finally, this sequence is followed by a 
nearly perfect 102-nucleotide ACC repeat containing a 
single T for C substitution. 
We next performed experiments to identify the pro- 
moter region of the gene. One of the PMCA3 mRNAs 
identified previously is approximately 4.5 kb in length and 
contains coding sequence and 3'-untranslated sequence 
totaling 3.6 kb, excluding the poly(A) tract [12]. Thus, the 
5'-untranslated sequence would not be expected to exceed 
approximately 900 nucleotides, leaving little room for 
additional sequence beyond the repeat element which ex- 
tends to nucleotide position -905.  For this reason it 
seemed likely that the transcription start site would be 
located just 5' to the repeat sequence. SI nuclease protec- 
tion experiments were performed using a 78-base synthetic 
oligonucleotide complementary to nucleotides -978  to 
- 901, which are immediately 5' of the trinucleotide repeat 
element (probe B, see Fig. 4). As shown in Fig. 2, multiple 
protected fragments were detected in the region between 
nucleotides -934  and -919,  with the sites around posi- 
tion - 934 corresponding to a consensus initiator site ([22], 
labeled INR in Fig. 4). Because these bands were very 
en 
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Fig. I. Sequence analysis of the 5' end of the rat PMCA 3 gene. The three 
panels show overlapping sequence determined using the chemical cleav- 
age procedure [21]. For each panel: lane 1, G reaction; lane 2, G+A 
reaction; lane 3, C+T reaction; lane 4, C reaction. The nucleotide 
sequence is numbered relative to the translation initiation site of the 
mature mRNA and extends from nucleotide -978  (lower left) in the 
5'-flanking sequence to approximately nucleotide -610  (upper right) in 
the first exon. Vertical lines delineate sequences corresponding Probe B 
(used for S1 nuclease protection and Northern blots), TCC and ACC 
trinucleotide tracts located between residues -901 and -688,  and the 5' 
end of rat PMCA3 cDNA clone RB7-2 [3] beginning at nucleotide - 695. 
Note the striking pattern of alternating TCC and ACC trinucleotide 
repeats that occur at the beginning of the 5'-untranslated sequence. 
faint we attempted to confirm the results using a 5' Rapid 
Amplification of cDNA Ends protocol (Clontech), in which 
brain mRNA was reversed transcribed, the first strand 
cDNA ligated to an anchor sequence, and the products 
amplified by PCR. However, these experiments were un- 
successful, possibly due to difficulties in reverse transcrib- 
ing the trinucleotide sequences and to the lack of a signifi- 
cant stretch of unique sequence preceding the trinu- 
cleotides. It should be noted that the first major TCC 
repeat is preceded by four GCT trinucleotides, and that the 
consensus initiator sequence and potential start sites identi- 
fied by S1 nuclease protection are within 5 to 20 nu- 
cleotides of the GCT trinucleotides. 
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Because the nuclease protection experiments provided 
only one piece of evidence regarding the location of the 
transcription initiation site, Northern blot hybridization 
was carried out to further examine the possibility that 
transcription initiation occurs within the region immedi- 
ately preceding the trinucleotide repeat sequence. The 
78-nucleotide SI probe (probe B) was PCR amplified and 
the antisense strand was uniformly labeled and used as a 
probe to analyze brain and skeletal muscle mRNA. Al- 
though the signals were very faint, as anticipated based on 
the small amount of sequence with which the probe was 
expected to hybridize (35 nucleotides or less), the more 
abundant 7.5 kb PMCA3 mRNA was clearly detected in 
brain (Fig. 3, panel B), which contains the highest levels of 
PMCA3 mRNA. This confirmed that the mature 7.5 kb 
brain mRNA contains at least a small amount of sequence 
5' to the repetitive lement. A trace signal was detected in 
the skeletal muscle mRNA sample as well, but it was not 
as evident as in the brain mRNA sample. The blot was 
then stripped and hybridized with probe A (see Fig. 4), 
which overlaps the 5' end of probe B but does not include 
the region containing the apparent transcription i itiation 
sites (Fig. 3, panel A). PMCA3 mRNAs were not detected 
with this probe, even after an autoradiographic exposure 
time of 17 days, indicating that sequences immediately 
upstream of the sites identified by SI nuclease protection 
are not included in the PMCA3 mRNA. The blot was then 
hybridized with probe C, which corresponds to the 3' end 
of exon 1 and spans nucleotides -585 to -411 (see Fig. 
4). This 175-nucleotide probe yielded strong signals (Fig. 
3, panel C) with all of the PMCA3 mRNAs identified 
previously [3]. 
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Fig. 2. S 1 nuclease protection analysis of the transcription i itiation site. Probe B, complementary to nucleotides -978  to -901 (underlined in Fig. 4) was 
5' end-labeled with 32 p, annealed with 50 /zg of tRNA, 50 /zg of rat skeletal muscle total RNA, or 50 ~g of rat brain total RNA. and digested with S 1 
nuclease as described [11]. The marker lanes (labeled according to the sense strand) are sequencing reactions in which a labeled primer complementary to 
nucleotides -901 to -925  was extended on a template consisting of a subcloned PstI fragment from the 5' end of the gene. The samples were 
fractionated on a DNA sequencing el and analyzed by autoradiography. The autoradiogram (left panel) revealed five protected fragments between 
nucleotide positions -934  and -919.  Because the signals were faint and did not reproduce well, the region of the autoradiogram containing the signals 
was scanned using N1H Image version 1.57, background was subtracted, and contrast was enhanced (right panel). 
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The results of the S I nuclease protection (Fig. 2) and 
Northern blot (Fig. 3) analyses trongly suggest hat initia- 
tion of PMCA3 gene transcription occurs at a cluster of 
sites located within 30 nucleotides of the trinucleotide 
repeat sequence, at least in the case of the 7.5 kb brain 
mRNA. Because the signal for the 7.5 kb skeletal muscle 
mRNA was very faint and a signal was not apparent for 
the 4.5 kb mRNA (possibly obscured by background), we 
cannot rule out the possibility that transcription of the 
skeletal muscle mRNA (particularly the 4.5 kb mRNA) 
also initiates at a site 3' to the trinucleotide repeat se- 
quence. Also, the possibility that transcription initiation 
occurs further upstream for one or more of the PMCA3 
mRNAs, with an additional exon being spliced to the 
region identified by probe B, cannot be entirely ruled out. 
This seems unlikely, however, due to the lack of good 
potential splice acceptor sites within this region. Although 
there are numerous AG dinucleotides in the upstream 
region, they either lack the polypyrimidine tract usually 
found before the splice acceptor site or are closely pre- 
ceded by another AG dinucleotide, which has not been 
observed within 15 nucleotides of known acceptor sites 
[23]. The presence of a good consensus initiator sequence 
[22] around position -935 ,  which corresponds to the 
5'-most protected fragments identified by nuclease protec- 
tion, lends additional support to the likelihood that this 
region contains the PMCA3 promoter. 
The sequence of the first exon, which includes the 
trinucleotide repeat sequence, and the sequence of the 
5'-flanking region of the PMCA3 gene are shown in Fig. 4. 
The region characterized contains 2839 base pairs of se- 
quence beyond that which was present in the PMCA3 
cDNA [3]. With regard to basic promoter elements, a 
consensus initiation site (INR) [22] is present at position 
- 935, consistent with the identified region of transcription 
initiation. The sequence does not contain a TATA box in 
close proximity to the putative initiator, but does contain a 
CCAAT motif as well as two potential SP1 binding sites 
within 250 base pairs of the putative initiator. The se- 
quence also contains two additional potential SPI sites 
(KRGGCKRRK) 3 [24] as well as a potential API binding 
site (TGASTMA) [24]. 
Because PMCA3 is expressed in skeletal muscle and 
brain it was of interest to examine the sequence for 
potential binding sites for muscle and brain specific tran- 
scription factors, Potential muscle specific transcription 
factor sites that were identified include: (1) four CArG 
sites that match the consensus equence (CCWWWWW- 
WGG) 3 [25] at 9 /10  positions, (2) fourteen perfect con- 
sensus E-Box sites (CANNTG) [26], (3) one perfect MCAT 
site (CATTCCT) [27] and ten sites that match the MCAT 
consensus equence at 6 /7  positions, and (4) two MADS- 
3 Standard IUPAC abbreviations: K = G or T, M = A or C, R = A or 
G, S=G or C, W= A or T, Y=C or T. 
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Fig. 3. Northern blot analysis of PMCA3 mRNAs. 15 ,ag of poly(A) + 
RNA from rat skeletal muscle and brain were analyzed as described [3]. 
The samples were hybridized first with a probe complementary to se- 
quence B, a 78-nucleotide s quence spanning the transcription initiation 
site that was also used for S1 nuclease analysis. The blot was then 
stripped and hybridized with a probe complementary to sequence A, a 
292-nucleotide sequence that overlaps probe B and is 5' to the transcrip- 
tion initiation site. The blot was then stripped and hybridized with a probe 
complementary to sequence C, a 175-nucleotide sequence from the 3' end 
of exon 1 that was present in the previously cloned PMCA3 cDNA. 
Panels are labeled according tothe probe used. Sequences corresponding 
to each probe are underlined in Fig. 4. The autoradiographic exposure 
time was 17 days for the probe A, 10 days for probe B, and 4 days for 
probe C. 
Box sites (YTAWWWTAR) [28] that match the consensus 
sequence at 9 /10  positions. Several potential brain tran- 
scription factor binding sites were identified including a 
perfect Octamer consensus ite (ATGCWAAT) [29] and 
two perfect POU consensus ites (GMATN =°~ 2, 3 WAAT). 
Particularly interesting was the presence of a potential 
BSF1 site that matched the consensus equence (GAGAG- 
GGGAGAGGRGRGAGRRG) [30] at 19/22 positions. 
This site was located in the antisense strand within a 
mirror repeat occurring in the second TCC trinucleotide 
element of the 5'-untranslated region. Further studies will 
be needed to confirm which, if any, of these potential 
transcription factor binding sites are involved in PMCA3 
gene regulation. 
In summary, our analysis of the 5' end of the PMCA3 
gene provides evidence that transcription initiation occurs 
at a cluster of sites between nucleotides -935  and -920  
relative to the translation initiation site (excluding intron 
sequences). The beginning of this cluster corresponds to a 
sequence with strong similarity to a consensus initiator 
sequence [19]. The PMCA3 promoter occurs within a 
relatively GC-rich sequence although, unlike the PMCA1 
promoter which is embedded in a CpG island [13], the 
PMCA3 promoter region contains very few CpG dinu- 
cleotides. The promoter lacks a TATA box but contains 
several potential SP1 sites and a CCAAT sequence, which 
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may serve as basic promoter elements. Also present are 
numerous sites that have the potential to be involved in the 
skeletal muscle and brain specificity of PMCA3 expres- 
sion. 
One of the most striking features of the PMCA3 gene is 
the presence of a complex trinucleotide repeat sequence of 
over 200 nucleotides. It is contained in the mature PMCA3 
mRNA and is located near the beginning of an unusually 
long 5'-untranslated sequence that is distributed over three 
exons spanning 20 kb of genomic DNA [12]. The presence 
of a potential binding site for the brain specific transcrip- 
tion factor BSFI [30] within the TCC trinucleotide tract 
located approximately 120 nucleotides downstream of the 
transcription start site is intriguing, particularly as it occurs 
within a subtle alteration in the trinucleotide pattern that 
forms the center of a perfect 80-nucleotide mirror-repeat. 
With regard to the possible regulatory significance of the 
trinucleotide repeats and the potential BSF1 site, it should 
be noted that sequences exhibiting mirror-repeat symmetry 
and containing primarily purines in one strand and pyrim- 
idines in the other strand tend to form unusual DNA 
structures and are often found in or near the promoter 
regions of eukaryotic genes [31]. 
Finally, it is worth noting that trinucleotide repeats have 
been implicated in several disease states including Fragile 
X Syndrome [15], Myotonic Dystrophy [16], and Hunting- 
ton's Disease [17]. While additional studies will be neces- 
sary to determine whether the trinucleotide repeat se- 
MCAT MC,~ff SPI 
- 3534 . . . . . . . . . . . . . . . . . . . . .  CTGCAGTAGCTGGTCCAGACAGTGTGCTTAAGGGTAGGACCAAGAGAAAAAGAGGAAAGGGGACAGGAAGGGAGCAGAGAATCAGCCTA 
CAsG 
- 3445 GTGC~TGTTCCCATCATGGGCATCTCTGGATCTGGCTCCTTAAAGATTCCCAGTTTAGGAAACTGGGACAGGCCTTGGTGTAAGGAAAAACATTCTAGCAAAAGCAACCA 
SPI MADS POU MCAT 
- 3335 GGAACCTGTTACTCCCTTTTCTTATTCTGGAGCCAGC~CTTCAAGCCATGAAGC4~GACCTAGTCTGATAAGTTC,GGCTGGTTCCAATTTTAATTCCTGATTCTAGGCAG 
E OCT 
- 3225 TAGAAGTCATGGAGTGTA~CATGC-C-GCTCTGAAAGTGTACCCAGTCTCTGAAGAACCAGATGCTAATTCCAAC-CATGGAC-CCTCTAGC~AGACCTACAGCAAACGACACTG 
E SPI E 
- 3115 TGCT~TTGTGGTGCTCTCAC~TGGAGGATAGCCAGTA~CCAGC4~AAAGCCACTTCTGTTGGAACAGAAAGAAAGGGTATAT~GGTGTCATGTGAGAG 
CArG MC~r API E E 
- 3005 TACACATATATGGACAGGAGTGT~AGGGACAGTGAGTAAGCATGGGTGTGGAAAGTAAATGTC~AAGTGCTh~-A.~r~TGGATGAATACTTGTGTGTGATGGGGGGACTCT 
- 2895 CTGTGTGTGTGACATTATACAA•TTTGCAAATCATAAGTGTGTGGGTGAATGTATGCAGGCCAGCTTATTTGAATGTAAGAAAATATGTGTAAGTGACCTTCTGTGAGTG 
E MC~ MCAT E E 
- 2785 TACATGAGCATGTGACTCTGTGTGATACATGAATGTGTGATTGTAGGTATGGGTGAA~AGTGGTGCTTAATGAGTGTGTGGAGTTGTGAGTGAACATGTGTGTGT 
E MCAT MADS 
- 2675 GTTGGGTGAGCATAAGGATATATAGGTGAACATGTGAGGATGTGTATTGGATGAATGTGCGGTGCTGTGAGCTTATAAATATGCATATTGGGTAATTGC~TGTGGATGAG 
E E MCAT 
- 2565 cAcTTGAATGTACATGTCAGATGAGTGTGGGATGGGATGAGTGTGTGAGTGTACATGTTGGTAACTATGGATGAGCATGAATGAGTGTGTATGTTGAA•AAGAACTGTGG 
- 2455 GTAGGTGTGAGGGAGTGAGTGTATATGTTGGATGAGTGTGGGGTAGGC~C~AAGTACATGAACATGCATGTTGGGTGAGCTAGGGCATGGCTGAATGTCAGTAAGTGTATG 
MCAT 
- 2345 TCCGGTGAGTGTGAGTTGGGGTAAGTAAGCACACGAGTGCATTTTGGTGAGTATATGTGTGAATGAATGAGTATAGATGTTGGGGAGTGTGTAGGTGAGCACATAAATGA 
E 
- 2235 ACATTGGCTGAGTGCAGGTGAGCGTGTCAATATGCATGGTGAGTATGGGGTGGGTGTGAATGAGTGCTCATATTGACTGAGTGTGAAGTGGTGTGAATGTGTGAGTGTTC 
- 2125 ATGTTGGGTTAGTATGGGTGGCTTATGAGTGTGTGTGTATGAGTGTGTAAGCA•TCTGCCTGTGCTGAGAAGTGCTGGTATCACCCCTGGATCTCTAGGAcCCCAGATCT 
MC/ff 
- 2015 CACTGGCCTTTCCACAGAACTAGCTGCTTCTGGGGAGAGGGACTGGCTATAGGAATGTGACCTCTGGcCCTGGCTGAGACCATGCAGTGCCATCTTGTGCTTTAGATAGA 
CAsG 
- 1905 TGTCTTACATAGCAGCAGTTCCTCAAAAAAATGCCTTCTCTGAACCCCAGGGCCATATTATGTCATCCCCAGTTAATGGTGTCTCCATATCCCCTATCCCAACTATCTGA 
E 
- 1795 GCAGTCACTGTCTGcCAGACACTTCTTTTcAGTAGACACCATGGTATCCACATCACC•CACTGAGCCAGGTGCATAGGTTCCCTTGGTGCCCTGTGTGTTCAGGTTTCTC 
CAsG 
- 1685 CATCCCCTCTCTCCAGTAGCTCTAGCTGGTGAAGTGACCCTTCATAGGTTTGGCCCATAGCCTTCTCAGAGGTTCAGCCCCTACTTCTATTCGCAGACCCAAAGCAAGGT 
- 1575 AGGATCTGGGGTCAGAGCTTCTGCTGTTCCAGAAGCTGGGAAAAGTACAGTGC~CCGTGCAGCTCCCCTCTGGTGGTCCAA~ACACACAGTGGCATGCTCACGCATG 
E 
- 1465 CAGGCTGGTAGGTACATGTCAGTGTCTGCTCTAGGGTATCCCCTGTACCTGTCTcTGGATGTCCACTTTTGAGTAGCATTGCCCACTTTGTCCTGAAAAAAATGTTCACT 
POU 
- 1355 ~ATAACCTTTAGC~ATCAGAGAGTGAAAATCTGTTATAAACTCCAGCTTCCCTCTGGGAAATGTATTTGGATGCCTGCACTCCCAGTGCTTACCAGGCAATTTCAGATA 
CCAAT 
-1245 A~-TA-C-~-~-~A'~-c~- (~ ' /~ 'C~-~C.~-~CA~AC~A~CCA~C~A~-~~C-C~9~GGTAGA.~AG~.q~T~TAG~'TAT9-~CC~T~CCC~A'G  ,A.. 
sP1 sPI 
- ~ 135 .~h~.~~~E~.T~T-c~.~.G.~.T~. .~e~-~.A .~T~T~g~q~qA~.~g~q~g~9.q~T~g~T~b~&~q~x&~A 
INR 
B S F I  
- 915 C TGCTGCTGCTCCTCCTCCTCCTCCTCCTCCTCCTCCTCCTCCTCCT~CTCCTCC~CCTCCTCCTCCACCACCACCAC~ACCACCACCACCACCACCTCCTCCTCCCTCT 
- 805 TCTCCCTCCTCCTCCAC•ACCACCACCACCACCACCACCATCACCACCACCAC•ACCACCACCACCACCACCA•CACCACCACCACCACCACCACCACCACCACCAC•AC 
- 695 C A ~ C A ~ C ~ . ~ T ~ T C ~ C ~ ' P ~ T C ~ T ~ T C C ~ C G C T c A C ~ C ~ T C . ~ c * ~ T ~ G ~ ~ G ~ ~ T ~ ~  
- 585 A(~/k~(~(~c~ACAG~CC%~TGGC~CC~AC~`~/rC~TGC~C~A~TC~CCA~GC~CCA6T~~6~~%~~A~ C 
-475 ¢4CaAGC~CC~ICAGCAACAGC~GCTACA~O~MI~:CCM~C.~FfGOCG~C~FI~CCCA~CC~/gt  ... Intron 1 
Fig. 4. Nucleotide sequence of the 5' end of the PMCA3 gene. Nucleotide sequence of the 5' flanking region and part of the first exon is shown, numbered 
with respect to the translation start site of the mature mRNA. The nucleotide sequences of probes A and B are underlined by dashed and solid lines, 
respectively. The nucleotide sequence of the portion of exon 1 present in the RB 7-2 cDNA is in bold type, while the portion of exon 1 used for probe C is 
underlined. Potential transcription factor binding sites (see text) are over-lined and labeled. 
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quence in the 5'-untranslated sequence of the PMCA3 
mRNA is involved in a disease process, the mapping of 
human PMCA3 to chromosome Xq28 [18] and its expres- 
sion in skeletal muscle and brain suggest that PMCA3 is a 
good candidate gene for skeletal muscle diseases uch as 
X-linked myotubular myopathy [32,33] or some of the 
neurological diseases that map to this region [ 19]. 
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